{"id":"rymphysia","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Takeda","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":["Alpha1-PI","TAK-883","A1PI","Alpha1-Proteinase Inhibitor (Human)","ARALAST NP"],"company":"Takeda","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=RYMPHYSIA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:03:29.297205+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:03:37.013484+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=RYMPHYSIA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:03:37.728354+00:00"}},"allNames":["rymphysia"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Rymphysia is a small molecule that binds to a specific protein or receptor, altering its function and leading to a therapeutic response. The exact mechanism of action and target of Rymphysia are currently unknown, making it difficult to provide further technical details."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=rymphysia","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=rymphysia","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:34:12.785759","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:03:40.136815+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"rymphysia","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05466747","phase":"PHASE4","title":"A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2024-01-01","conditions":["Chronic Obstructive Pulmonary Disease (COPD)","Alpha1-Antitrypsin Deficiency"],"enrollment":0,"completionDate":"2029-05-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Takeda","relationship":"Original Developer"}],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"Takeda","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"RYMPHYSIA","companyName":"Takeda","companyId":"takeda","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:03:40.136815+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}